

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	FI	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/534,978 11/09/2005		Zhuangwu Li	159976	4719		
38598	7590	12/14/2006		EXAMINER		
	/S KURTI EET, N.W.		THOMAS, DAVID C			
SUITE 110	•	•		ART UNIT	PAPER NUMBER	
WASHING	TON, DC	20005	1637			

DATE MAILED: 12/14/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
,	10/534,978	LI ET AL.	
Office Action Summary	Examiner	Art Unit	
	David C. Thomas	1637	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with	he correspondence address	_
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICA: 36(a). In no event, however, may a reply rill apply and will expire SIX (6) MONTHS cause the application to become ABANI	FION.  be timely filed  from the mailing date of this communication.  DONED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on			
• • • • • • • • • • • • • • • • • • • •	action is non-final.		
3) Since this application is in condition for allowar	nce except for formal matters	, prosecution as to the merits is	
closed in accordance with the practice under E			
Disposition of Claims			
4) Claim(s) 1-20 is/are pending in the application.			
4a) Of the above claim(s) is/are withdraw	vn from consideration.		
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.	•		
7) Claim(s) is/are objected to.			
8) Claim(s) 1-20 are subject to restriction and/or e	election requirement.		
Application Papers	•	· .	
9) The specification is objected to by the Examine	r.		
10) The drawing(s) filed on is/are: a) acce		the Examiner.	
Applicant may not request that any objection to the	•		
Replacement drawing sheet(s) including the correcti			
11) The oath or declaration is objected to by the Ex	aminer. Note the attached O	ffice Action or form PTO-152.	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 11	9(a)-(d) or (f).	
a) ☐ All b) ☐ Some * c) ☐ None of:		•	
<ol> <li>Certified copies of the priority documents</li> </ol>	s have been received.		
. 2. Certified copies of the priority documents	s have been received in Appl	ication No	
3. Copies of the certified copies of the prior		eived in this National Stage	
application from the International Bureau			
* See the attached detailed Office action for a list of	of the certified copies not rec	eived.	
; ;			
Attachment(s)			
1) Notice of References Cited (PTO-892)		mary (PTO-413)	
2)  Notice of Draftsperson's Patent Drawing Review (PTO-948) 3)  Information Disclosure Statement(s) (PTO/SB/08)	Paper No(s)/M 5) Notice of Infor	all Date mal Patent Application	
Paper No(s)/Mail Date	6) Other:	· · · • • · · · · · · · · · · · · · · ·	

Art Unit: 1637

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-15 and 20, drawn to a method for detecting and quantifying telomerase activity in a biological sample and a method for monitoring the effectiveness of treatment of a subject with an agent that inhibits telomerase activity.

Group II, claim(s) 16-19, drawn to a kit for detecting telomerase activity, comprising reaction tubes comprising first and second reaction mixtures separated by a wax layer, and control tubes comprising a first and third reaction mixtures separated by a wax layer.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Group I, drawn to claims 1-15 and 20, included at least one claim which was found to be anticipated by the prior art, specifically, Burger et al. (Euro. J. Cancer (1997) 33, 638-644), which is shown to be an X reference which anticipates the methods claims. As MPEP 1893.03(d) notes "The expression special technical features is defined as meaning those technical features that define the contribution which each claimed invention, considered as a whole, makes over the prior art." In the current case, the claims are drawn to a method in Group I, but that Group does not make a contribution over the prior art because the invention is anticipated by the prior art. Therefore, there is no

Art Unit: 1637

single inventive concept under PCT Rule 13.1 and the lack of unity requirement is proper.

3. The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised

Art Unit: 1637

that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement may be traversed (37 CFR 1.143).
- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to David C. Thomas whose telephone number is 571-272-3320. The examiner can normally be reached on 5 days, 9-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

Art Unit: 1637

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

David C. Thomas 12/11/06

Assistant Examiner

Art Unit 1637

gary/benzion, Ph/0/ Rvisøry patent examiner Page 5

TECHNOLOGY CENTER 1600